Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT7MRGU)

DTT Name Chymotrypsin (CTR)
Gene Name CTR
DTT Type
Clinical trial target
 [1]
BioChemical Class
Peptidase
UniProt ID
NOUNIPROTAC
TTD ID
T61484

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pancrecarb DMOML9Q Pancreatic malfunction DC30-DC3Z NDA filed [1]
CM-AT DMLMN2F Attention deficit hyperactivity disorder 6A05.Z Phase 3 [2]
Liprotamase DMNF4UH Cystic fibrosis CA25 Phase 3 [3]
------------------------------------------------------------------------------------
2 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
JBP-1 DM0KMPN Solid tumour/cancer 2A00-2F9Z Investigative [1]
POP-1 DMVTKCX Solid tumour/cancer 2A00-2F9Z Investigative [1]
------------------------------------------------------------------------------------

References

1 US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
2 Drugmakers dance with autism. Nat Biotechnol. 2010 Aug;28(8):772-4.
3 Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.